Tilray/Aphria in Europe since 2017. Now Oldweed says Cura knows where to invest. Comical
I would say Cura is following Tilray, one of the pioneers of European Medical Cannabis with 20% Market share in Germany.
Borris knows where the growth is but, this has to put the cash balance close to Nil!
https://tilraymedical.eu.com/#:~:text=Tilray%20Europe&text=In%20Europe%2C%20Tilray%2C%20as%20a,patient%20use%20in%20multiple%20conditions. Demecan, one of the three companies licensed to cultivate in Germany.
He told the Business of Cannabisthe move would give local firms a significant leg up.
“We are now free to cultivate as much cannabis as we want and can choose the strains we want to grow,” he said.
“Finally there will be a level playing field and German cultivators can compete properly with importers. Given our lower production costs and easy logistics, we will hopefully see a boom in medical cultivation in Germany.”
He added the three current licence holders – Demecan, Aurora and Tilray – will “probably” benefit the most given their first-mover advantage.
https://www.cannabiz.com.au/now-its-germanys-turn-to-welcome-a-level-playing-field/